Genzyme Rival Gets FDA Nod
Luke Timmerman8/17/09
Protalix BioTherapeutics, an Israel-based biotech company, said today it has received FDA approval for a treatment protocol of its experimental drug for Gaucher’s disease, which will allow patients to get expanded access to the drug during a shortage of the leading therapy, Genzyme’s imiglucerase (Cerezyme). Shares of Protalix (AMEX: PLX) climbed 10 percent in mid-day trading on the news.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
